Memphasys

Memphasys AAQS

Vrijednost AAQS od Memphasys (MEM.AX) na dan 22. окт 2026. je 4. Prethodne godine, AAQS je bio 4,00 — promjena od 0,00% (niži).

AAQS

4

YoY

0,00%

Zadnja ažuriranja:

Memphasys ima trenutni AAQS od 4. Visok AAQS može se smatrati pozitivnim pokazateljem da se preduzeće uspešno razvija. Investitori mogu očekivati da je kompanija na dobrom putu da ostvari dobit. S druge strane, važno je posmatrati AAQS deonice Memphasys u poređenju sa ostvarenom dobiti i drugim preduzećima iste branše. Visok AAQS nije apsolutna garancija za pozitivnu budućnost. Samo tako se može dobiti kompletna slika o performansama kompanije. Da bi se bolje procenio razvoj preduzeća, važno je posmatrati AAQS u poređenju sa drugim kompanijama iste branše. Generalno, investitori bi uvek trebali da posmatraju AAQS kompanije u kontekstu sa drugim finansijskim pokazateljima kao što su dobit, EBIT, Cash Flow i drugi, kako bi doneli obrazovane odluke o investiranju.

Istorija Memphasys AAQS

  • 3 године

  • 10 година

  • 25 godina

  • Максимално

AAQS
Datum
AAQS
1. јан 2019.
4,00 AUD
1. јан 2020.
4,00 AUD
1. јан 2021.
4,00 AUD
1. јан 2022.
4,00 AUD
1. јан 2023.
4,00 AUD
1. јан 2024.
4,00 AUD
1. јан 2025.
4,00 AUD
1. јан 2026.
4,00 AUD
Istorija Memphasys AAQS
ГОДИНАAAQSYoY
40,00%
40,00%
40,00%
40,00%
40,00%
40,00%
40,00%
40,00%
40,00%
40,00%
40,00%
40,00%
4—

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

Memphasys Анализа акција

Šta radi Memphasys? Memphasys Ltd. develops medical devices, diagnostics, and media for assisted reproduction technology (ART) in humans and animals. The company's product pipeline includes Felix, a patented automated device for separating high-quality sperm from semen in human IVF procedures, ROSA, an in vitro diagnostic for assessing oxidative stress in semen and blood samples, and AI-Port, a system for storing and transporting animal semen without freezing for up to four days. Felix targets the global IVF market, ROSA serves clinics and research facilities analyzing reproductive health, and AI-Port is designed for livestock artificial insemination providers. The company monetizes through direct sales of these proprietary products to healthcare providers, fertility clinics, and agricultural biotechnology firms. Felix, with its patented technology for DNA-safe sperm separation, addresses a significant market need in human fertility treatments. ROSA provides diagnostic capabilities for clinics evaluating oxidative stress in reproductive samples, while AI-Port offers a competitive advantage in livestock breeding by eliminating the need for frozen semen transport. These products are sold directly to specialized buyers within their respective sectors without intermediaries. The company generates revenue primarily from the sale of its three core products: Felix for human IVF, ROSA for diagnostic assessments, and AI-Port for animal semen storage and transport. These products target distinct segments—human fertility clinics, reproductive health research institutions, and livestock artificial insemination businesses—each with clear purchasing patterns and demand drivers. Memphasys focuses on selling directly to these end-users rather than through third-party distributors. Memphasys je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji Memphasys

AAQS kompanije Memphasys iznosi 4 u 2026. godini.

Na Eulerpool-u možete pronaći potpuni historijski razvoj AAQS Memphasys od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

AAQS je pokazatelj koji je razvila kompanija AlleAktien.

AAQS je pokazatelj koji je razvila kompanija AlleAktien.

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

Квалитет — Memphasys

Sve ključne metrike — Memphasys

Раст